
BioMarin and n-Lorem Partner to Target Rare ReNU Syndrome
BioMarin Pharmaceutical and the n-Lorem Foundation have entered a global licensing agreement to develop the first-ever treatment for ReNU syndrome. The collaboration focuses on an investigational antisense oligonucleotide therapy designed to address the underlying genetic cause of the neurodevelopmental condition, which was only identified in 2024.



























